A Phase 2 interventional study of 18F fluciclovine in Brain Metastases, sponsored by Blue Earth Diagnostics. Completed at 9 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-07-20.
Sponsored by Blue Earth Diagnostics (part of Bracco) · Phase 2, Interventional, and Diagnostic
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 1,443 studies in Brain Neoplasms with a site in United States — 229 open to participants now, 352 under way, 18 of them phase 3. Brain Neoplasms · United States.
Among the 1,443 studies in Brain Neoplasms with a site in United States, this one is the 699th largest by enrollment of the 1,188 interventional ones that give a count, is one of 43 that started in 2020, is one of 383 in phase 2, and was the 1,117th registered.
2,441 studies on the registry are indexed under Brain Neoplasms; 541 are open to participants now.
Browse Brain Neoplasms studies →229 of the 1,443 studies in Brain Neoplasms with a site in United States are open now. Recruiting first, the newest first:
Brian J.Gill · Sites in United States
Ages 22–65
Stanford University · Sites in United States
Ages 6 mo–25 yrs
University of California, San Francisco · Sites in United States
Ages 18+
Beijing Inno Medicine Co., Ltd. · Sites in United States, China
Ages 18–70
University of Florida · Sites in United States
Ages 18–80
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 425 Brain Neoplasms studies recruiting now, 286 (67%) set no upper age limit and 82 (19%) stop at 75 or younger; 80 take children under 18; 36 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
1,443 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 552 · Phase 2 520 · Phase 3 72 · Phase 4 18
First in 1979; this study’s year is marked. 43 started in 2020.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 23 is below the median of 40 across 1,832 interventional studies indexed under Brain Neoplasms.
Median enrollment 30 across the 1,188 interventional studies, 76 across the 191 observational. Of the 993 that completed or were terminated, 355 (36%) have results posted.
This tab as a report to print or save as PDF → With an account.
221 of 1,443 have an industry lead sponsor. The 10 most frequent:
This study is registered under Blue Earth Diagnostics, one of the names counted as Bracco. Under that name alone:
Blue Earth Diagnostics is the lead sponsor of 12 studies on the registry; 3 are open to participants now.
Of its 5 completed or terminated interventional studies of FDA-regulated products, 5 (100%) have results posted.
Bracco has 3 studies filed under Brain Neoplasms — fewer than ten, so there is no comparison to draw.
141 of the studies in Brain Neoplasms with a site in United States that are under way reach primary completion within a year, 8 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT00978458Phase 3Eastern Cooperative Oncology GroupRadiation Therapy With or Without Temozolomide in Treating Patients With Low-Grade Glioma | 2026-12-31 |
| NCT03741673Phase 3M.D. Anderson Cancer CenterPre-operative SRS or Post-operative SRS in Treating Cancer Patients With Brain Metastases | 2027-01-31 |
| NCT05438212Phase 3NRG OncologyComparing the Addition of Radiation Either Before or After Surgery for Patients With Brain Metastases | 2027-03-16 |
| NCT05271240Phase 3Northwell HealthRepeated Superselective Intraarterial Cerebral Infusion (SIACI) of Bevacizumab With Temozolomide and Radiation Compared to Temozolomide and Radiation Alone in Newly Diagnosed GBM | 2027-04-01 |
| NCT00950001Phase 3M.D. Anderson Cancer CenterStereotactic Radiosurgery Compared to Observation in Treating Patients With Brain Metastases | 2027-04-30 |
Add all 141 to your calendar (.ics) → With an account.
Among the 1,443 studies in Brain Neoplasms with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
An Open-label, Single-arm, Single-dose, Prospective, Multicenter Phase 2b Study to Establish Image Interpretation Criteria for 18F-Fluciclovine Positron Emission Tomography (PET) in Detecting Recurrent Brain Metastases After Radiation Therapy
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
1. Patients with a history of active hematological
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Brain metastases
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Single intravenous administration of 18F fluciclovine for PET Scan
Drug: 18F fluciclovine
18F fluciclovine injection, 185 MegaBecquerel (MBq) (5 Millicurie (mCi)) ± 20%, delivered as an intravenous bolus
Also known as: Axumin
Sensitivity of 18F Fluciclovine PET for Detecting Recurrent Brain Metastases at Different Visual Thresholds
Sensitivity is calculated as % of participants with positive histopathology who are classified as positive on their 18F fluciclovine PET (i.e. true positive). Each participant had one lesion, therefore results are representative of both subject and lesion level sensitivity. Three readers evaluated the PET scans to classify 18F fluciclovine uptake in study lesions according to 4 incremental categories: absent, mild, moderate or marked. Three different thresholds of 18F fluciclovine uptake were then applied to calculate the sensitivity: Mild or Higher Uptake, Moderate or Higher Uptake, Marked Uptake. As an example, for calculating sensitivity based on the threshold of Mild or Higher Uptake, all participants with positive histopathology, classified by a reader as having mild, moderate or marked 18F fluciclovine uptake, would be categorized as true positive. This calculation was then repeated on the other two threshold categories, to produce sensitivities at different thresholds.
Time frame: 60 days
Specificity of 18F Fluciclovine PET for Detecting Recurrent Brain Metastases at Different Visual Thresholds
Specificity is calculated as the % of participants with negative histopathology who are classified as negative on their 18F fluciclovine PET (i.e. true negative). Each participant had 1 lesion, therefore results are representative of both subject and lesion level specificity. 3 readers evaluated the PET scans to classify 18F fluciclovine uptake in study lesions according to 4 incremental categories: absent, mild, moderate or marked. 3 different thresholds of uptake were then applied to calculate the specificity: Mild or Higher Uptake, Moderate or Higher Uptake, Marked Uptake. Example, for calculating specificity based on the threshold of Moderate or Higher Uptake, all participants with negative histopath, classified by a reader as having absent or mild uptake (i.e. not classified by a reader as having moderate or marked uptake), would be categorized as true negative. This calculation was repeated on the other 2 threshold categories, to produce specificities at different thresholds
Time frame: 60 days
Sensitivity of 18F Fluciclovine PET for Detecting Recurrent Brain Metastases Based on Quantitative and Dynamic Measures of Lesion 18F Fluciclovine Uptake
Sensitivity calculated as %participants with positive histopath and positive on PET (i.e. true positive). Each participant had 1 lesion, results represent both subject and lesion level sensitivity. Sensitivity is calculated using positive PET classified by quantitative and dynamic measures. Quantitative measure is based on lesion standardized uptake value (SUV). Receiver Operating Characteristic (ROC) analysis of all participant lesion SUV was performed. ROC analyses was performed to select a SUV threshold for calculating sensitivity. Sensitivity calculation: participants with positive histopath and SUV = or \> threshold are positive on scan. Dynamic measure: 3 readers evaluated PET scans to classify uptake pattern based on 4 categories: Type 0, Type I, Type II, Type III. Sensitivity is calculated for each type of uptake pattern (example: calculating sensitivity based on Type I pattern, participants with positive histopath, classified as Type I, would be categorized as true positive).
Time frame: 60 days
Specificity of Different Thresholds of Quantitative and Dynamic Measures of Lesion 18F Fluciclovine Uptake.
Specificity is calculated as %participants with negative histopath and negative on PET (i.e. true negative). Each participant had 1 lesion, results represent both subject and lesion level specificity. Specificity is calculated using negative PET classified by quantitative and dynamic measures. Quantitative measure is based on lesion standardized uptake value (SUV). Receiver Operating Characteristic (ROC) analysis of all participant lesion SUV was performed. ROC analyses was performed to select a SUV threshold for calculating sensitivity. Specificity calculation: participants with negative histopath, SUV \< threshold are negative on scan. Dynamic measure: 3 readers evaluated PET scans to classify uptake pattern based on 4 categories: Type 0, Type I, Type II, Type III. Specificity is calculated for each type of uptake pattern (example, calculating specificity based on Type I pattern, participants with negative histopath, classified as Type I, would be categorized as true negative)
Time frame: 60 days
Treatment-emergent Adverse Events
Safety will be assessed from data on the occurrence of one or more treatment-emergent Adverse Events from the time of intravenous administration of 18F fluciclovine until 1 day post-18F-fluciclovine administration.
Time frame: From the time of administration of 18F fluciclovine until 1 day post-18F-fluciclovine administration.
Subjects with a history of brain metastases previously treated with primary, adjuvant, or repeat (salvage) radiation therapy, with a recent standard of care (SoC) brain magnetic resonance imaging (MRI) found to be equivocal for recurrent brain metastasis, and who met all the inclusion criteria and none of the exclusion criteria, were consented and enrolled. Subjects were screened between 28Oct2020 and 30Dec2021. Nine clinical research sites in the US participated in the study.
| Milestone | 18F-Fluciclovine Injection |
|---|---|
| Started | 23 |
| Underwent 18f-fluciclovine pet | 23 |
| Completed | 23 |
| Not completed | 0 |
Sensitivity is calculated as % of participants with positive histopathology who are classified as positive on their 18F fluciclovine PET (i.e. true positive). Each participant had one lesion, therefore results are representative of both subject and lesion level sensitivity. Three readers evaluated the PET scans to classify 18F fluciclovine uptake in study lesions according to 4 incremental categories: absent, mild, moderate or marked. Three different thresholds of 18F fluciclovine uptake were then applied to calculate the sensitivity: Mild or Higher Uptake, Moderate or Higher Uptake, Marked Uptake. As an example, for calculating sensitivity based on the threshold of Mild or Higher Uptake, all participants with positive histopathology, classified by a reader as having mild, moderate or marked 18F fluciclovine uptake, would be categorized as true positive. This calculation was then repeated on the other two threshold categories, to produce sensitivities at different thresholds.
| percentage of participants | 18F-Fluciclovine Injection |
|---|---|
| Mild or Higher Uptake = Positive : Central Reader 1 | 100 (69.2 to 100) |
| Mild or Higher Uptake = Positive : Central Reader 2 | 100 (69.2 to 100) |
| Mild or Higher Uptake = Positive : Central Reader 3 | 100 (69.2 to 100) |
| Moderate or Higher Uptake = Positive : Central Reader 1 | 100 (69.2 to 100) |
| Moderate or Higher Uptake = Positive : Central Reader 2 | 100 (69.2 to 100) |
| Moderate or Higher Uptake = Positive : Central Reader 3 | 90 (55.5 to 99.8) |
| Marked Uptake = Positive : Central Reader 1 | 80 (44.4 to 97.5) |
| Marked Uptake = Positive : Central Reader 2 | 40 (12.2 to 73.8) |
| Marked Uptake = Positive : Central Reader 3 | 60 (26.2 to 87.8) |
Specificity is calculated as the % of participants with negative histopathology who are classified as negative on their 18F fluciclovine PET (i.e. true negative). Each participant had 1 lesion, therefore results are representative of both subject and lesion level specificity. 3 readers evaluated the PET scans to classify 18F fluciclovine uptake in study lesions according to 4 incremental categories: absent, mild, moderate or marked. 3 different thresholds of uptake were then applied to calculate the specificity: Mild or Higher Uptake, Moderate or Higher Uptake, Marked Uptake. Example, for calculating specificity based on the threshold of Moderate or Higher Uptake, all participants with negative histopath, classified by a reader as having absent or mild uptake (i.e. not classified by a reader as having moderate or marked uptake), would be categorized as true negative. This calculation was repeated on the other 2 threshold categories, to produce specificities at different thresholds
| percentage of participants | 18F-Fluciclovine Injection |
|---|---|
| Mild or Higher Uptake = Positive : Central Reader 1 | 0 (0.0 to 24.7) |
| Mild or Higher Uptake = Positive : Central Reader 2 | 0 (0.0 to 24.7) |
| Mild or Higher Uptake = Positive : Central Reader 3 | 0 (0.0 to 24.7) |
| Moderate or Higher Uptake = Positive : Central Reader 1 | 38.5 (13.9 to 68.4) |
| Moderate or Higher Uptake = Positive : Central Reader 2 | 30.8 (9.1 to 61.4) |
| Moderate or Higher Uptake = Positive : Central Reader 3 | 46.2 (19.2 to 74.9) |
| Marked Uptake = Positive : Central Reader 1 | 92.3 (64.0 to 99.8) |
| Marked Uptake = Positive : Central Reader 2 | 100 (75.3 to 100.0) |
| Marked Uptake = Positive : Central Reader 3 | 100 (75.3 to 100.0) |
Sensitivity calculated as %participants with positive histopath and positive on PET (i.e. true positive). Each participant had 1 lesion, results represent both subject and lesion level sensitivity. Sensitivity is calculated using positive PET classified by quantitative and dynamic measures. Quantitative measure is based on lesion standardized uptake value (SUV). Receiver Operating Characteristic (ROC) analysis of all participant lesion SUV was performed. ROC analyses was performed to select a SUV threshold for calculating sensitivity. Sensitivity calculation: participants with positive histopath and SUV = or \> threshold are positive on scan. Dynamic measure: 3 readers evaluated PET scans to classify uptake pattern based on 4 categories: Type 0, Type I, Type II, Type III. Sensitivity is calculated for each type of uptake pattern (example: calculating sensitivity based on Type I pattern, participants with positive histopath, classified as Type I, would be categorized as true positive).
| percentage of participants | 18F-Fluciclovine Injection |
|---|---|
| Quantitative SUV ≥ 4.8 = Positive : Central Reader 1 | 80 (44.4 to 97.5) |
| Quantitative SUV ≥ 4.8 = Positive : Central Reader 2 | 80 (44.4 to 97.5) |
| Quantitative SUV ≥ 4.8 = Positive : Central Reader 3 | 80 (44.4 to 97.5) |
| Dynamic Type 0: Central Reader 1 | 0 (0 to 30.9) |
| Dynamic Type 0 : Central Reader 2 | 0 (0 to 30.9) |
| Dynamic Type 0 : Central Reader 3 | 0 (0 to 30.9) |
| Dynamic Type I: Central Reader 1 | 80 (44.4 to 97.5) |
| Dynamic Type I: Central Reader 2 | 90 (55.5 to 99.8) |
| Dynamic Type I: Central Reader 3 | 100 (69.2 to 100) |
| Dynamic Type II: Central Reader 1 | 10 (0.3 to 44.5) |
| Dynamic Type II: Central Reader 2 | 10 (0.3 to 44.5) |
| Dynamic Type II: Central Reader 3 | 0 (0 to 30.9) |
| Dynamic Type III: Central Reader 1 | 10 (0.3 to 44.5) |
| Dynamic Type III: Central Reader 2 | 0 (0 to 30.9) |
| Dynamic Type III: Central Reader 3 | 0 (0 to 30.9) |
Specificity is calculated as %participants with negative histopath and negative on PET (i.e. true negative). Each participant had 1 lesion, results represent both subject and lesion level specificity. Specificity is calculated using negative PET classified by quantitative and dynamic measures. Quantitative measure is based on lesion standardized uptake value (SUV). Receiver Operating Characteristic (ROC) analysis of all participant lesion SUV was performed. ROC analyses was performed to select a SUV threshold for calculating sensitivity. Specificity calculation: participants with negative histopath, SUV \< threshold are negative on scan. Dynamic measure: 3 readers evaluated PET scans to classify uptake pattern based on 4 categories: Type 0, Type I, Type II, Type III. Specificity is calculated for each type of uptake pattern (example, calculating specificity based on Type I pattern, participants with negative histopath, classified as Type I, would be categorized as true negative)
| percentage of participants | 18F-Fluciclovine Injection |
|---|---|
| SUV ≥ 4.8 : Central Reader 1 | 84.6 (54.6 to 98.1) |
| SUV ≥ 4.8 : Central Reader 2 | 84.6 (54.6 to 98.1) |
| SUV ≥ 4.8 : Central Reader 3 | 84.6 (54.6 to 98.1) |
| Dynamic Type 0 : Central Reader 1 | 100 (75.3 to 100) |
| Dynamic Type 0 : Central Reader 2 | 100 (75.3 to 100) |
| Dynamic Type 0 : Central Reader 3 | 100 (75.3 to 100) |
| Dynamic Type I : Central Reader 1 | 7.7 (0.2 to 36.0) |
| Dynamic Type I : Central Reader 2 | 15.4 (1.9 to 45.5) |
| Dynamic Type I : Central Reader 3 | 0 (0 to 24.7) |
| Dynamic Type II : Central Reader 1 | 92.3 (64.0 to 99.8) |
| Dynamic Type II : Central Reader 2 | 84.6 (54.6 to 98.1) |
| Dynamic Type II : Central Reader 3 | 100 (75.3 to 100) |
| Dynamic Type III : Central Reader 1 | 100 (75.3 to 100) |
| Dynamic Type III : Central Reader 2 | 100 (75.3 to 100) |
| Dynamic Type III : Central Reader 3 | 100 (75.3 to 100) |
Safety will be assessed from data on the occurrence of one or more treatment-emergent Adverse Events from the time of intravenous administration of 18F fluciclovine until 1 day post-18F-fluciclovine administration.
| Participants | 18F-Fluciclovine Injection |
|---|---|
| Subjects reporting at least 1 TEAE | 1 |
| Nervous System Disorders (Headache) | 1 |
Collected over Safety was assessed from the time of 18F-fluciclovine administration until 1 day post18Ffluciclovine administration based on reported adverse events (AEs) and serious adverse events (SAEs); treatment emergent adverse events (TEAE).. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| 18F-Fluciclovine Injection | 0/23 (0%) | 0/23 (0%) | 1/23 (4.3%) |
| Event | 18F-Fluciclovine Injection |
|---|---|
| HeadacheNervous system disorders | 1/23 |
| Age, Continuous(years) | Patients |
|---|---|
| Mean | 59.8 ± 11.88 |
| Sex: Female, Male(Participants) | Patients |
|---|---|
| Female | 16 |
| Male | 7 |
| Ethnicity (NIH/OMB)(Participants) | Patients |
|---|---|
| Hispanic or Latino | 8 |
| Not Hispanic or Latino | 15 |
| Unknown or Not Reported | 0 |
| Race (NIH/OMB)(Participants) | Patients |
|---|---|
| American Indian or Alaska Native | 0 |
| Asian | 0 |
| Native Hawaiian or Other Pacific Islander | 0 |
| Black or African American | 2 |
| White | 20 |
| More than one race | 0 |
| Unknown or Not Reported | 1 |
| Region of Enrollment(participants) | Patients |
|---|---|
| United States | 23 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Aug 2020 to primary completion in Dec 2021, 16 months.
Results were first posted in Aug 2023, 1 year 7 months after primary completion.
Of 44 industry-sponsored phase 2 interventional studies under Brain Neoplasms, half reached primary completion within 43 months of starting (the median), counting those still running; a quarter within 24 and three quarters within 55. This study's 16 months is below that.
Counting every sponsor, half of 252 studies reached it within 61 months; a quarter within 38 and three quarters within 98.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jul 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Fluciclovine F-18